2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.Peer-Reviewed Original ResearchRefractory to irinotecanArm ATAS-102DNA methyltransferase inhibitorArm BRates of progression free survivalB. Median overall survivalEvidence of target modulationMetastatic colorectal cancer patientsResistant to systemic therapyTreatment related adverse eventsProgression free survivalPhase II studyPhase II trialKaplan-Meier ratesRelated adverse eventsColorectal cancer patientsFree survivalOverall survivalSystemic therapyAdverse eventsIrinotecanRegorafenibCancer patientsGuadecitabine
2017
High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ. High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer 2017, 3: 191-199. PMID: 28824947, PMCID: PMC5545919, DOI: 10.3233/blc-170104.Peer-Reviewed Original ResearchSurgical margin statusBladder cancerGenitourinary surgeryMargin statusInstitutional experienceIntra-operative radiation therapyRadiation therapyHigh-risk bladder cancerPositive surgical margin statusMulti-institutional registryRecurrence-free survivalEffective local controlGI complicationsSarcomatoid histologyAdvanced diseaseFree survivalComplication rateOverall survivalPrimary outcomeRetrospective reviewSuch patientsRecurrent tumorsUrothelial cancerWound infectionUrothelial histology